{
  "id": "5c5f2cef1a4c55d80b000022",
  "type": "yesno",
  "question": "There is no drug available to prevent HIV infection, Pre-exposure prophylaxis (PrEP), yes or no?",
  "ideal_answer": "Pre-exposure prophylaxis (PrEP) with the drug combination Truvada can substantially decrease HIV transmission in individuals at risk.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26746652",
    "http://www.ncbi.nlm.nih.gov/pubmed/27900502",
    "http://www.ncbi.nlm.nih.gov/pubmed/28370177",
    "http://www.ncbi.nlm.nih.gov/pubmed/21799568",
    "http://www.ncbi.nlm.nih.gov/pubmed/29278542",
    "http://www.ncbi.nlm.nih.gov/pubmed/27177804",
    "http://www.ncbi.nlm.nih.gov/pubmed/28657199",
    "http://www.ncbi.nlm.nih.gov/pubmed/23570850",
    "http://www.ncbi.nlm.nih.gov/pubmed/23972284",
    "http://www.ncbi.nlm.nih.gov/pubmed/25987851"
  ],
  "snippets": [
    {
      "text": "pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657199",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29278542",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Following US Food and Drugs Administration approval in July 2012 of daily oral tenofovir and emtricitabine for pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk individuals in the USA, there has been much controversy about the implementation of this PrEP regimen in other countries throughout the world, and in Europe in particular.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23972284",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daily oral pre-exposure prophylaxis (PrEP) is the use of antiretroviral drugs by HIV-negative people to prevent HIV infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27900502",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "HIV pre-exposure prophylaxis (PrEP) is a new approach that involves the ongoing use of antiretroviral medications by HIV-negative individuals to reduce the risk of HIV infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987851",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS Combined ART + PrEP is likely to prevent more HIV infections than either strategy alone, but with higher prevalence of drug resistance.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23570850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION Use of pre-exposure prophylaxis (PrEP) among people who inject drugs (PWID) has been shown to be effective in preventing HIV transmission.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27177804",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pre-exposure prophylaxis (PrEP) is an experimental approach to HIV prevention and consists of antiretroviral drugs to be taken before potential HIV exposure in order to reduce the risk of HIV infection and continued during periods of risk.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21799568",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "HIV pre-exposure prophylaxis (PrEP) is the use of one or more antiretroviral medications (in combination) to prevent HIV infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28370177",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The most commonly used PrEP medication (Truvada<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28370177",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The use of antiretrovirals as pre-exposure prophylaxis (PrEP) is highly efficacious in HIV prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26746652",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}